source
- Argenx's Vyvgart fails to beat placebo in Phase 3 Sjögren's disease trialArgenx announced that its marketed antibody therapy Vyvgart did not show superiority over placebo in a Phase 3 study involving patients with Sjögren's disease, a chronic autoimmune condition. The…
- Roche partners with China's Defand Therapeutics to discover molecular glue medicinesRoche announced a collaboration with Chinese biotech Defand Therapeutics aimed at discovering new molecular glue medicines for oncology and immune‑mediated diseases. Unlike typical licensing deals…